Differential effects of olanzapine, haloperidol and risperidone on calcitonin gene-related peptide in the rat brain

Neuropeptides

Volumn 42, Issue 5-6, 2008, Pages 535-541

  Angelucci, Francesco ^a,b   Gruber, Susanne H M ^a   Caltagirone, Carlo ^b   Mathé, Aleksander A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

CGRP; Haloperidol; Olanzapine; Rat brain; Risperidone

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG INHIBITION; FRONTAL CORTEX; HYPOTHALAMUS; IMMUNOCOMPETENT CELL; MALE; NONHUMAN; OCCIPITAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CALCITONIN GENE-RELATED PEPTIDE; HALOPERIDOL; MALE; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RISPERIDONE;

RATTUS;

EID: 56349148237     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2008.06.002     Document Type: Article

References (60)

1. Abdul-Monim Z., Reynolds G.P., and Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav. Brain Res. 169 (2006) 263-273
2. Amara S.G., Jonas V., Rosenfeld M.G., Ong E.S., and Evans R.M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298 (1982) 240-244
3. Angelucci F., Aloe L., Gruber S., Fiore M., and Mathé A.A. Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyltransferase in rat brain regions. Int. J. Neuropsychopharmacol. 3 (2000) 13-25
4. Angelucci F., Aloe L., and Mathé A.A. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered following haloperidol and risperidone administration. J. Neurosci. Res. 60 (2000) 783-794
5. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., and Mathé A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 15 (2005) 311-317
6. Antonova E., Kumari V., Morris R., Halari R., Anilkumar A., Mehrotra R., and Sharma T. The relationship of structural alterations to cognitive deficits in schizophrenia: a voxel-based morphometry study. Biol. Psychiat 58 (2005) 457-467
7. Aravagiri M., Yuwiler A., and Marder S.R. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 139 (1998) 356-363
8. Barkataki I., Kumari V., Das M., Taylor P., and Sharma T. Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder. Behav. Brain Res. 169 (2006) 239-247
9. Burvenich S., Unsicker K., and Krieglstein K. Calcitonin gene-related peptide promotes differentiation, but not survival, of rat mesencephalic dopaminergic neurons in vitro. Neuroscience 86 (1998) 1165-1172
10. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., and Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124 (1996) 87-94
11. Bymaster F., Perry K.W., Nelson D.L., Wong D.T., Rasmussen K., Moore N.A., and Calligaro D.O. Olanzapine: a basic science update. Br. J. Psychiat. Suppl. 37 (1999) 36-40
12. Cipriani A., Rendell J.M., and Geddes J.R. Haloperidol alone or in combination for acute mania. Cochrane Database Syst. Rev. 3 (2006) CD004362
13. Clementi G., Grassi M., Valerio C., Prato A., Fiore C.E., and Drago F. Effects of calcitonin gene-related peptide on extrapyramidal motor system. Pharmacol. Biochem. Behav. 42 (1992) 545-548
14. Cohrs S., Roher C., Jordan W., Meier A., Huether G., Wuttke W., Ruther E., and Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 185 (2006) 11-18
15. Deutch A.Y., and Roth R.H. Calcitonin gene-related peptide in the ventral tegmental area: selective modulation of prefrontal cortical dopamine metabolism. Neurosci. Lett. 74 (1987) 169-174
16. Dhillo W.S., Small C.J., Jethwa P.H., Russell S.H., Gardiner J.V., Bewick G.A., Seth A., Murphy K.G., Ghatei M.A., and Bloom S.R. Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology 144 (2003) 1420-1425
17. Drumheller A., Menard D., Fournier A., and Jolicoeur F.B. Neurochemical effects of CGRPa. Ann. NY Acad. Sci. 657 (1992) 546-548
18. Edvinsson L., and Petersen K.A. CGRP-receptor antagonism in migraine treatment. CNS Neurol. Disord. Drug Targets 6 (2007) 240-246
19. Fallin M.D., Lasseter V.K., Avramopoulos D., Nicodemus K.K., Wolyniec P.S., McGrath J.A., Steel G., Nestadt G., Liang K.Y., Huganir R.L., Valle D., and Pulver A.E. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 77 (2005) 918-936
20. Fountoulakis K.N., Grunze H., Panagiotidis P., and Kaprinis G. Treatment of bipolar depression: an update. J. Affect. Disorders 109 (2008) 21-34
21. 3H]dopa in various regions of the brain. J. Neurochem. 13 (1966) 655-669
22. Gruber S.H., and Mathé A.A. Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum. J. Neurosci. Res. 61 (2000) 458-463
23. Gruber S.H.M., and Mathé A.A. Effects of amphetamine and dopamine receptor antagonists on calcitonin gene-related peptide, neuropeptide Y and neurotensin in rat brain. Neuropsychopharmacology 23 (2000) S2-S118
24. Gruber S.H.M., Nomikos G., and Mathé A.A. Dopamine receptor antagonists prevent the d-amphetamine-induced increase in calcitonin gene-related peptide levels in the ventral striatum. J. Neurosci. Res. 64 (2001) 606-611
25. Gruber S.H.M., Nomikos G., and Mathé A.A. Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat. Neuropsychopharmacology 26 (2002) 595-604
26. Gruber S.H.M., Nomikos G., and Mathé A.A. Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs. Eur. Neuropsychopharmacol. 16 (2006) 592-600
27. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 38 (2004) 524-529
28. Husum H., Termeer E., Mathé A.A., Bolwig T.G., and Ellenbroek B.A. Early maternal deprivation alters hippocampal levels of neuropeptide Y and calcitonin-gene related peptide in adult rats. Neuropharmacology 42 (2002) 798-806
29. Ishida-Yamamoto A., and Tohyama M. Calcitonin gene-related peptide in the nervous tissue. Prog. Neurobiol. 33 (1989) 335-386
30. Jolicoeur F.B., Menard D., Fournier A., and St-Pierre S. Structure-activity analysis of CGRP's neurobehavioral effects. Ann. NY Acad. Sci. 657 (1992) 154-163
31. Kovacs A., and Telegdy G. Effect of calcitonin gene-related peptide on passive avoidance behavior in rats. Role of transmitters. Ann. NY Acad. Sci. 657 (1992) 543-545
32. Kovacs A., and Telegdy G. Behavioural impairment induced by calcitonin gene-related peptide (CGRP) antiserum in passive avoidance reflex in rats. Neuropeptides 26 (1994) 233-236
33. Kovacs A., and Telegdy G. Effects of CGRP on active avoidance behavior in rats. Physiol. Behav. 58 (1995) 429-435
34. Kovacs A., Telegdy G., Toth G., and Penke B. Neurotransmitter mediated open-field behavioral action of CGRP. Life Sci. 64 (1999) 733-740
35. Krahn D.D., Gosnell B.A., Levine A.S., and Morley J.E. Effects of calcitonin gene-related peptide on food intake. Peptides 5 (1984) 861-864
36. Levine A.S., and Morley J.E. Neuropeptide Y: a potent inducer of consummatory behavior in rats. Peptides 5 (1984) 1025-1029
37. Li X.M., Perry K.W., Wong D.T., and Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136 (1998) 153-161
38. Lutz T.A., Rossi R., Althaus J., Del Prete E., and Scharrer E. Evidence for a physiological role of central calcitonin gene-related peptide (CGRP) receptors in the control of food intake in rats. Neurosci. Lett. 230 (1997) 159-162
39. Mathé A.A., Jousisto-Hanson J., Stenfors C., and Theodorsson E. Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. J. Neurosci. Res. 26 (1990) 233-237
40. Mathé A.A., Stenfors C., Brodin E., and Theodorsson E. Neuropeptides in brain: effects of microwave irradiation and decapitation. Life Sci. 46 (1990) 287-293
41. Mathé A.A., Ågren H., Lindström L., and Theodorsson E. Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients. A possible trait marker of major depressive disorder. Neurosci. Lett. 182 (1994) 138-142
42. Mathé A.A., Hertel P., Nomikos G.G., Gruber S., Mathé J.M., and Svensson T.H. The psychotomimetic drugs d-amphetamine and phencyclidine release calcitonin gene-related peptide in the limbic forebrain of the rat. J. Neurosci. Res. 46 (1996) 316-323
43. Mathé A.A., Gruber S., Jimenez P.A., Theodorsson E., and Stenfors C. Effects of electroconvulsive stimuli and MK-801 on Neuropeptide Y, Neurokinin A, and Calcitonin Gene-Related peptide in rat brain. Neurochem. Res. 22 (1997) 629-636
44. Mathé A.A., Agren H., Wallin A., and Blennow K. Calcitonin gene-related peptide and calcitonin in the CSF of patients with dementia and depression: possible disease markers. Prog. Neuropsychopharmacol. Biol. Psychiat. 26 (2002) 41-48
45. Mathé A.A., Beiderbeck D.I., Gruber S.H.M., El Khoury A., Landgraf R., and Neumann I.D. Neuropeptide Y, calcitonin gene-related peptide and CRH in brain of rats bred for high anxiety-related behaviors. Neuropsychopharmacology 31 Suppl. 1 (2006) 46
46. Miklowitz D.J., and Johnson S.L. The psychopathology and treatment of bipolar disorder. Annu. Rev. Clin. Psychol. 2 (2006) 199-235
47. Poore L.H., and Helmstetter F.J. The effects of central injections of calcitonin gene-related peptide on fear-related behavior. Neurobiol. Learn. Mem. 66 (1996) 241-245
48. Sachs G.S., and Gardner-Schuster E.E. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiat. Scand. Suppl. 434 (2007) 27-34
49. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., and Sumiyoshi T. Psychosis pathways converge via D2(high) dopamine receptors. Synapse 60 (2006) 319-346
50. Sigmundsson T., Suckling J., Maier M., Williams S., Bullmore E., Greenwood K., Fukuda R., Ron M., and Toone B. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am. J. Psychiat. 158 (2001) 234-243
51. Smith L.A., Cornelius V., Warnock A., Tacchi M.J., and Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord. 9 (2007) 551-560
52. Sørensen G., Lindberg C., Wörtwein G., Bolwig T.G., and Woldbye D.P. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. 77 (2004) 723-729
53. Stanley B.G., and Leibowitz S.F. Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci. 35 (1984) 2635-2642
54. Steenbergh P.H., Hoppener J.W.M., Zandberg J., Visser A., Lips C.G.M., and Jansz H.S. Structure and expression of the human calcitonin/CGRP genes. FEBS Lett. 209 (1986) 97-103
55. Theodorsson E., Stenfors C., and Mathé A.A. Microwave irradiation increases recovery of neuropeptides from brain tissues. Peptides 11 (1990) 1191-1197
56. Van Rossum D., Hanisch U.K., and Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci. Biobehav. Rev. 21 (1997) 649-678
57. Venken T., and Del-Favero J. Chasing genes for mood disorders and schizophrenia in genetically isolated populations. Hum. Mutat. 28 (2007) 1156-1170
58. Woldbye D.P., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., and Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat. Med. 3 (1997) 761-764
59. Wörtwein G., Husum H., Andersson W., Bolwig T.G., and Mathé A.A. Effects of maternal separation on neuropeptide Y and calcitonin gene-related peptide in "depressed" flinders sensitive line rats: a study of gene-environment interactions. Prog. Neuropsychopharmacol. Biol. Psychiatry. 30 (2006) 684-689
60. Yamasue H., Iwanami A., Hirayasu Y., Yamada H., Abe O., Kuroki N., Fukuda R., Tsujii K., Aoki S., Ohtomo K., Kato N., and Kasai K. Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiat. Res. 131 (2004) 195-207